Biotech company Biogen presents data for its experimental Alzheimer’s drug after terminating studies in March
Biogen Inc. on Thursday tried to make the case for why two aborted studies of its experimental Alzheimer’s disease drug support its plan to seek approval from U.S. regulators, but skeptics said they remained unconvinced that the drug is effective.
Biogen presented additional details from the studies at the Clinical Trials on Alzheimer’s Disease conference in San Diego, and said the new data showed that patients receiving the highest dose of the drug appeared to have slower declines in their cognitive abilities than patients...
México Últimas Noticias, México Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
New Biogen data showed no major safety issues for its Alzheimer's drugBiogen Inc on Thursday presented new data on its experimental Alzheimer's d...
Leer más »
Biogen's stock rises 4% after releasing new data on late-stage Alzheimer's drugAnalysts who parsed through it, said the lack of any new negatives in the report means that they expect the company will take the data to the Food and Drug Administration.
Leer más »
New Biogen data showed no major safety issues for its Alzheimer's drugBiogen Inc on Thursday presented new data on its experimental Alzheimer's d...
Leer más »
New details emerge on drug that may slow Alzheimer’s diseaseExcitement and skepticism have surrounded the drug since its developers stopped studies earlier this year because it didn't seem to be working.
Leer más »
Drug curbs delusions, eases anger in Alzheimer's patients, researchers findIf regulators approve it, the drug could become the first new medicine for Alzheimer's patients in nearly two decades.
Leer más »
Drug can curb dementia’s delusions, researchers findSAN DIEGO (AP) — A drug that curbs delusions in Parkinson's patients did the same for people with Alzheimer's disease and other forms of dementia in a study that was stopped early because the...
Leer más »